RxDoctor Payments Data

Shuo Wang, MD

Internal Medicine · Los Angeles, CANPI 1538232137

Payments from drug & device makers

$1,417in general payments, 2019–2025

Across 28 payments — averaging $50.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$361
  • Samsung HME America, Inc.$196
  • Medtronic$173
  • Johnson & Johnson$150
  • Paratek Pharmaceuticals, Inc.$125
  • Sunovion Pharmaceuticals Inc.$119
  • plus $293 from 8 others

What the payments were for

  • Food & beverage$1,33094%
  • Education$876%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,417 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$658,458
Medicare patients
1,410
Services billed
6,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban387$114,137
Austedo XrDeutetrabenazine20$106,008
SantylCollagenase Clostridium Hist.20$63,290
JardianceEmpagliflozin153$51,517
IngrezzaValbenazine Tosylate13$32,303
PrezcobixDarunavir/Cobicistat13$31,268
Metformin Er GastricMetformin Hcl32$28,610
IsentressRaltegravir Potassium14$27,417
TrulicityDulaglutide24$23,490
OzempicSemaglutide21$21,498
XareltoRivaroxaban64$19,407
RayaldeeCalcifediol25$15,195
Etravirine13$14,151
FarxigaDapagliflozin Propanediol47$13,858
NuedextaDextromethorphan Hbr/Quinidine17$13,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$361$106,00820 claims
Smith+NephewSantyl$23$63,29020 claims
Johnson & JohnsonPrezcobix, Xarelto$150$50,67577 claims
Neurocrine Biosciences, Inc.Ingrezza$85$32,30313 claims
GSKArexvy, Breo Ellipta$12$13,89142 claims
AbbVieVraylar$32$12,95321 claims
AmgenEpogen$21$12,13619 claims
Otsuka America Pharmaceutical, Inc.Rexulti$47$9,49518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →